Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
Indications Acute myeloid leukaemia; Brain cancer; CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Leukaemia; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms PIVOT IO 020
Sponsors Bristol-Myers Squibb

22 Mar 2023 Status changed from completed to discontinued.
01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
14 Jul 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com